Vision

To be the best in the diagnostic field and make diagnostics affordable and easily available to the common man.

Mission

To achieve excellence in Biotechnology and utilize it’s power for the good of humanity, and ensure that the Corporate objectives are met.

Quality Policy

We, the Management and Employees, at Yashraj Biotechnology Limited are committed to serve our customers. Here is our Quality Policy.

We are a research and innovation driven, UL registered and ISO 13485:2016, ISO 9001:2015 and OHSAS 18001:2007 certified company, established during 1999 in Navi Mumbai, Maharashtra, India. We have operations in Germany, USA and soon in South Korea. Our research, development and production-related activities encompass a whole range of native, recombinant and cell-derived antigens; and monoclonal antibodies. Highest standards of quality and unwavering commitment towards healthcare innovation have enabled us to capture some of the biggest market segments for various biomarker antigens and antibodies it develops.

The products manufactured by YBL encompass a whole range of disease markers, including infectious diseases, various cancers, cardiac, renal, liver, neurological and autoimmune disorders. YBL has developed more than fifty high pure native antigens, sourced from various human biological fluids, including CRP, CA15-3, CA125, CA19-9, CA72-4, HBsAg-Ad and HBsAg-Ay, AIM etc in close collaboration with the diagnostic companies. With an emphasis on long term stability and specificity, our antigens are tested in multiple platforms for quality by Immunonephelometry, Immunoturbidimetry, Latex Agglutination, ECLIA and ELISA to ensure batch to batch consistency and by PCR and US-FDA approved CLIA for compliance and safety.

We encourage and facilitate the creation, discovery, dissemination and application of new knowledge and foster academic alliances. We have entered in the area of induced pluripotent stem cell-derived disease specific models for high-throughput drug screening and toxicology testing. A bio-repository of human clinical specimens from patients with broad clinical categories of cancer has been established to isolate their cellular derivatives (primary cancer cells, blood-derived iPSCs, iPSC-derived differentiated cardiomyocytes and hepatocytes).Through this program we plan to contribute to new drug discovery; personalized medicine for patients; and stem cell and tissue banking.

Research and Development (R&D) work at YBL is approved by the Department of Science and Industrial Research, Ministry of Science and Technology, Government of India.

Come and partner with us at Yashraj Biotechnology Limited in our quest to make diagnostics affordable and accessible!

Our History

Our Affiliations

Our Certifications